Skip to main content

Advertisement

ADVERTISEMENT

News

News
05/23/2024

Stephanie Holland 

Stephanie Holland 
According to results from the phase 2 RELATIVITY-060 study, the addition of relatlimab to nivolumab and chemotherapy did not improve objective response among patients with unresectable, locally advanced or metastatic gastric or...
According to results from the phase 2 RELATIVITY-060 study, the addition of relatlimab to nivolumab and chemotherapy did not improve objective response among patients with unresectable, locally advanced or metastatic gastric or...
According to results from the...
05/23/2024
Oncology
News
04/24/2024

Stephanie Holland 

Stephanie Holland 
Based on results from the NETTER-P and NETTER-1 studies, the FDA has approved lutetium Lu 177 dotatate for pediatric patients aged 12 and older with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors.
Based on results from the NETTER-P and NETTER-1 studies, the FDA has approved lutetium Lu 177 dotatate for pediatric patients aged 12 and older with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors.
Based on results from the...
04/24/2024
Oncology
News
04/08/2024

Stephanie Holland 

Stephanie Holland 
The FDA granted accelerated approval to trastuzumab deruxtecan for patients with unresectable or metastatic HER2-positive solid tumors who have received systemic treatment and have no alternative treatment options.
The FDA granted accelerated approval to trastuzumab deruxtecan for patients with unresectable or metastatic HER2-positive solid tumors who have received systemic treatment and have no alternative treatment options.
The FDA granted accelerated...
04/08/2024
Oncology

Advertisement

Conference Coverage
01/19/2024

Stephanie Holland 

Stephanie Holland 
According to primary analysis results from the phase 3 NETTER-2 study, first-line [177Lu] Lu-DOTA-TATE significantly prolonged PFS and demonstrated a clinically meaningful ORR among patients with newly diagnosed, advanced grade 2 and 3...
According to primary analysis results from the phase 3 NETTER-2 study, first-line [177Lu] Lu-DOTA-TATE significantly prolonged PFS and demonstrated a clinically meaningful ORR among patients with newly diagnosed, advanced grade 2 and 3...
According to primary analysis...
01/19/2024
Oncology
Conference Coverage
01/19/2024

Stephanie Holland 

Stephanie Holland 
According to primary analysis results from the phase 3 NETTER-2 study, first-line [177Lu] Lu-DOTA-TATE significantly prolonged PFS and demonstrated a clinically meaningful ORR among patients with newly diagnosed, advanced grade 2 and 3...
According to primary analysis results from the phase 3 NETTER-2 study, first-line [177Lu] Lu-DOTA-TATE significantly prolonged PFS and demonstrated a clinically meaningful ORR among patients with newly diagnosed, advanced grade 2 and 3...
According to primary analysis...
01/19/2024
Oncology
Conference Coverage
01/19/2024

Janelle Bradley

Janelle Bradley
First-line treatment with atezolizumab and bevacizumab plus chemotherapy provides PFS advantage vs atezolizumab plus placebo and chemotherapy for patients with advanced biliary tract cancer, according to findings from the phase 2 IMbrave151...
First-line treatment with atezolizumab and bevacizumab plus chemotherapy provides PFS advantage vs atezolizumab plus placebo and chemotherapy for patients with advanced biliary tract cancer, according to findings from the phase 2 IMbrave151...
First-line treatment with...
01/19/2024
Oncology

Advertisement

Conference Coverage
01/18/2024
Allison Casey
According to results from the phase 3 SKYSCRAPER-08, tiragolumab plus atezolizumab and chemotherapy improved the progression-free survival and overall survival among patients with esophageal squamous cell carcinoma.
According to results from the phase 3 SKYSCRAPER-08, tiragolumab plus atezolizumab and chemotherapy improved the progression-free survival and overall survival among patients with esophageal squamous cell carcinoma.
According to results from the...
01/18/2024
Oncology
News
10/16/2023

Allison Casey

Allison Casey
In a phase 3 clinical trial, thrombosis rates of patients with gastrointestinal and lung cancer with high-risk profiles were mitigated to those comparable to the rates of patients with low-risk profiles with a risk-directed primary...
In a phase 3 clinical trial, thrombosis rates of patients with gastrointestinal and lung cancer with high-risk profiles were mitigated to those comparable to the rates of patients with low-risk profiles with a risk-directed primary...
In a phase 3 clinical trial,...
10/16/2023
Oncology
News
10/13/2023

Allison Casey 

Allison Casey 
According to results from a phase 2 basket study, tucatinib plus trastuzumab demonstrated antitumor activity and was well-tolerated among patients with previously treated HER2-positive metastatic biliary tract cancer.
According to results from a phase 2 basket study, tucatinib plus trastuzumab demonstrated antitumor activity and was well-tolerated among patients with previously treated HER2-positive metastatic biliary tract cancer.
According to results from a...
10/13/2023
Oncology

Advertisement

Zev Wainberg, MD, UCLA
Videos
08/22/2023

Featuring Zev Wainberg, MD 

Featuring Zev Wainberg, MD 
At the 2023 World Congress on Gastrointestinal Cancers, Zev Wainberg, MD, presented results from the final analysis of the phase 2 FIGHT trial.
At the 2023 World Congress on Gastrointestinal Cancers, Zev Wainberg, MD, presented results from the final analysis of the phase 2 FIGHT trial.
At the 2023 World Congress on...
08/22/2023
Oncology

Advertisement